Skip to content
Open access

Biological consistency and molecular heterogeneity in synchronous endometrial and ovarian carcinomas: a clinicopathological study within the FIGO 2023 framework

Aug 2026 · Journal of Ovarian Research · Vol 19 · 0 citations · 21 references
Medicine

TL;DR

Paired molecular profiling (p53 and MMR) highlights the value of assessing tumor heterogeneity and clonal evolution for refined risk stratification and suggests clinical management may benefit from integrating molecular risk features to better distinguish true concordant SEOC from independent aggressive malignancies.

Abstract

The 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system introduced Stage IA3 to categorize a subset of synchronous endometrial and ovarian carcinomas (SEOC) with favorable outcomes. This study aims to evaluate the clinical and biological rationale of the FIGO 2023 Stage IA3 criteria by analyzing paired molecular profiles and assessing the prognostic impact of ovarian versus endometrial clinicopathological features. A retrospective cohort of 48 SEOC patients was evaluated and stratified into three cohorts: Group A (Stage IA3, n = 12), Group B (Advanced Concordant, n = 26), and Group C (Independent Discordant, n = 10). Survival outcomes were assessed alongside clinical interventions. Given the retrospective design, clonal relationships were assessed in a sub-cohort of 17 patients for whom complete paired immunohistochemistry (IHC) data for mismatch repair (MMR) proteins and p53 were available for both tumor sites. Univariate analysis showed that ovarian factors, including histological grade and lymph node metastasis, were significantly associated with overall survival (OS, p < 0.01). In contrast, endometrial parameters, such as myometrial invasion (MI) depth and FIGO stage, did not show statistical significance (all p > 0.5). Group A had a 5-year OS of 90.9%, while Group B showed a 5-year OS of 95.5%, and Group C showed 70.0%. Among the 17 cases with paired IHC testing, molecular discordance was identified in 29.4% (5/17) overall, all of which occurred within the non-IA3 group, yielding a discordance rate of 38.5% (5/13 in non-IA3 group vs. 0% in Stage IA3 group). Notably, Case 29 exhibited concordant p53 mutational patterns but divergent MMR status between the endometrial and ovarian lesions. In conclusion, our preliminary findings suggest that the FIGO 2023 Stage IA3 classification defines a biologically consistent, low-risk cohort, offering a potential rationale for exploring future treatment de-escalation. Furthermore, paired molecular profiling (p53 and MMR) highlights the value of assessing tumor heterogeneity and clonal evolution for refined risk stratification. Clinical management may benefit from integrating molecular risk features to better distinguish true concordant SEOC from independent aggressive malignancies, particularly in histologically discordant cases.

Read PDF

Similar papers

Review Oct 2026

Comparative prognostic performance of the FIGO 2023 and FIGO 2009 staging systems integrated with molecular classification in endometrial cancer: a retrospective single-centre cohort study.

BACKGROUND The 2023 revision of the International Federation of Gynecology and Obstetrics (FIGO) staging system incorporates molecular classification, aggressive histology, and substantial lymphovascular space invasion (LVSI) as key determinants. Its prognostic performance compared with FIGO 2009 requires validation in...

Weigi Xia, Bing-Jie Liu, Rui Kong et al. · 0 citations
Open access Sep 2026

Molecular Profile of Advanced Endometrial Cancer (FIGO III–IV) in a Polish Multicentre Cohort: Clinicopathological Characterisation and Treatment Implications

The molecular profile of advanced endometrial cancer may inform treatment strategy; the therapeutic implications presented here are descriptive and hypothesis-generating, as the study did not include survival data.

W. Szatkowski, Aleksandra Dudek, K. Franczyk et al. · 0 citations
Review Open access Sep 2026

Prognostic and Clinicopathological Significance of CD74 Expression in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid malignancies, and reliable prognostic biomarkers are urgently needed to guide risk stratification and treatment. CD74 has been implicated in tumor progression, invasion, and pro-inflammatory signaling in various cancers. This systematic review...

I. Vacariu, S. Ilie, C. Vere et al. · 0 citations
Open access Oct 2026

Retrospective analysis of patients with locally advanced or metastatic urothelial carcinoma treated in Argentina (2018–2025): results from the GUIA 2 study in real-world clinical practice

This first multicentre RWE study of la/mUC in Argentina shows treatment patterns and outcomes comparable to international cohorts, and confirms the survival benefit of maintenance therapy and underscores the importance of regional data to optimise urothelial cancer care in Latin America.

Pablo E. Companys, Tomás Soulé, Mariano Aymar et al. · 0 citations
Open access Oct 2026

Molecular and Clinicopathological Characteristics Predict Fertility-Sparing Treatment Outcomes in Endometrial Atypical Hyperplasia and Endometrioid Endometrial Cancer.

It is suggested that integrating molecular classification with clinicopathological characteristics can improve prognostic assessment and support individualized management for patients undergoing FST.

Tian-Wei Xing, Kun Wei, Yang-Yang He et al. · 0 citations
Review Open access Oct 2026

MODERN APPROACHES TO HIGH-RISK ENDOMETRIAL CANCER DIAGNOSIS AND TREATMENT: A CASE OF MISMATCH REPAIR-DEFICIENT ENDOMETRIOID ADENOCARCINOMA, FIGO STAGE IVC

Relevance: Endometrial cancer is one of the most common gynecological malignancies worldwide, and its incidence continues to rise. Advanced-stage, high-risk endometrial cancer, particularly tumors with mismatch repair deficiency (MMRd), presents substantial diagnostic and therapeutic challenges despite recent advances...

D. Kaldybekov, D. Kaidarova, E. Kukubasov et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.